Efficacy of mosapride versus domperidone in the treatment of functional dyspepsia and its effects on gastric motility indexes and gastrointestinal hormone levels / 中国基层医药

Objective:To investigate the efficacy of mosapride versus domperidone in the treatment of functional dyspepsia and its effects on gastric motility indexes and gastrointestinal hormone levels. Methods:Ninety-four patients with functional dyspepsia who received treatment in Huzhou Linghu People's Hospital between May 2019 and May 2021 were included in this study. They were randomly assigned to undergo treatment with either domperidone (control group, n = 47) or mosapride (study group, n = 47). Efficacy was compared between the two groups. Results:Total response rate in the study group was significantly higher than that in the control group ( χ2 = 5.04, P = 0.025). After medication, motilin, plasma leptin and corticotropin-releasing hormone in the study group were (184.22 ± 25.36) μg/mL, (18.57 ± 2.44) μg/L, (7.21 ± 1.14) pg/mL, respectively, which were superior to those in the control group [(111.25 ± 21.00) μg/mL, (15.41 ± 2.28) μg/L, (9.02 ± 1.32) μg/mL, t = 15.19, 6.48, 16.23, P < 0.001, < 0.001, < 0.001]. After medication, cholecystokinin, somatostatin, vasoactive intestinal peptide and gastrin levels in the study group were (45.36 ± 5.12) ng/L, (5.48 ± 1.25) ng/L, (86.35 ± 12.11) pg/mL, and (105.24 ± 12.05) ng/L, respectively, which were significantly superior to those in the control group [(50.21 ± 6.18) ng/L, (7.01 ± 0.98) ng/L, (98.75 ± 14.18) pg/mL and (97.35 ± 11.48) ng/L, t = 4.14, 6.60, 4.55, 3.25, P < 0.001, < 0.001, < 0.001, < 0.002]. The recurrence rate in the study group was significantly lower than that in the control group (2.13% vs. 27.66%, χ2 = 4.66, P = 0.031). The incidence of adverse reactions in the study group was significantly lower than that in the control group (14.89% vs. 34.04%, χ2 = 10.80; P = 0.001). Conclusion:Mosapride has a better therapeutic effect on functional dyspepsia, exhibits a greater effect on improving gastric motility indexes and gastrointestinal hormone levels, and leads to a lower incidence of recurred functional dyspepsia than domperidone. Therefore, mosapride for treatment of functional dyspepsia deserves clinical promotion.

Effect of electroacupuncture combined with mosapride on gastric motility in diabetic gastroparesis rats / 中国针灸

OBJECTIVE@#To observe the effect of electroacupuncture (EA) at "Zusanli" (ST 36) combined with mosapride on gastric emptying rate and gastric motility in the rats with diabetic gastroparesis.@*METHODS@#Using random number table method, 68 male SD rats were divided into a blank group (12 rats) and a model establishment group (56 rats). In the model establishment group, the models of diabetic gastroparesis were established with intraperitoneal injection of streptozotocin combined with high-fat and high-sugar diet. Six weeks later, the successful rat models in the model establishment group were randomized into a model group, an EA group, a mosapride group and a combined treatment group, 12 rats in each one. In the EA group, EA was exerted at "Zusanli" (ST 36) (disperse-dense wave, 2 Hz/15 Hz in frequency, 2 mA in intensity) for 20 min. In the mosapride group, mosapride was intervened with intragastric administration (2 mg/kg). In the combined treatment group, electroacupuncture at "Zusanli" (ST 36) was combined with intragastric administration of mosapride. The intervention was given once daily in each group. There was 1 day at interval after 6-day intervention, consecutively for 5 weeks. At the end of intervention, the random blood glucose, gastric emptying rate and the data of gastric motility (average intra-gastric pressure, amplitude and frequency of gastric motility) were detected.@*RESULTS@#Compared with the blank group, blood glucose was increased in the model group (P<0.001). Blood glucose was reduced in the EA group, the mosapride group and the combined treatment group as compared with the model group separately (P<0.001, P<0.01), whereas, compared with the mosapride group, blood glucose was decreased in the combined treatment group (P<0.05). In comparison with the blank group, the gastric emptying rate, the average intra-gastric pressure and the amplitude of gastric motility were all decreased in the model group (P<0.001) and the frequency of gastric motility was increased (P<0.001). Gastric emptying rate, the average intra-gastric pressure and the amplitude of gastric motility were increased in the EA group, the mosapride group and the combined treatment group (P<0.01, P<0.05, P<0.001) and the frequency of gastric motility was decreased (P<0.001) as compared with the model group respectively. Compared with the EA group, the average intra-gastric pressure and the amplitude of gastric motility were increased in the combined treatment group (P<0.001). In comparison with the mosapride group, the gastric emptying rate, the average intra-gastric pressure, the amplitude and frequency of gastric motility in the combined treatment group, as well as the frequency of gastric motility in the EA group were all increased (P<0.05, P<0.001, P<0.01).@*CONCLUSION@#Electroacupuncture at "Zusanli" (ST 36) combined with intragastric administration of mosapride could regulate blood glucose and improve the gastric motility in the rats with diabetic gastroparesis. The effect is better than either simple electroacupuncture or mosapride.

Treatment of postprandial discomfort syndrome in the elderly: a multi-centered prospective randomized controlled clinical study / 中华内科杂志

Objective@#To evaluate the efficacy and safety of Oryz-Aspergillus enzyme and pancreatin tablets (Combizym®) in the treatment of postprandial distress syndrome (PDS) in the elderly, compared with gastrointestinal motility drugs.@*Methods@#A prospective randomized controlled trial was designed and registered in the China Clinical Trials Registry (ChiCTR-IPR-16008185). The elderly patients with PDS were randomly divided into three groups, including Mosapride group with Mosapride citrate tablets 5 mg 3 times per day for 2 weeks; Combizym® group with Combizym tablets 244 mg 3 times per day for 2 weeks; combined treatment group with both drugs and same doses for 2 weeks. The modified Nepean dyspepsia index (NDSI) score, discomfort intensity score and PDS score were calculated on patients before treatment, at the end of first and second week of treatment, as well as 4 weeks after treatment finished, respectively. Adverse effects were evaluated.@*Results@#A total of 323 patients from 16 tertiary hospitals in China were enrolled in this study. Among them, 105 patients were in Mosapride group, 109 in Combizym® group and 109 in combined treatment group. There were 148 males (45.8%) and 175 females (54.2%) with median age 71.4±9.0 years (60-100 years). Baseline characteristics of three groups were comparable. After treatment, the NDSI scores in three groups all decreased significantly (P<0.001), while they were similar between groups (P>0.05). The discomfort intensity score and PDS score in three groups showed a significant reduction after treatment (P<0.001), especially in the combined treatment group. Compared with Mosapride group, the scores in Combizym® group decreased significantly after one or two weeks [discomfort intensity score: after one week, 4.0(2.5, 8.0) vs. 6.0(3.0, 10.0); after two weeks, 3.0(0.0, 5.0) vs. 4.0(2.0, 6.0); all P<0.05. PDS score: after one week, 6.0(3.0, 9.0) vs. 7.0(3.5, 10.5); after two weeks, 3.0(0.0, 5.0) vs. 4.0(2.0, 7.0); all P<0.05]. The efficacy rate in all patients after first week of treatment was over 15.0%. The efficacy rates after two weeks were 55.2%, 68.8% and 73.4% in Mosapride group, Combizym® group and combined treatment group, respectively. After two week treatment, the efficacy rates in Combizym® group (P=0.041) and combined group (P=0.006) were higher than that of Mosapride group. The recurrence rate of Mosapride group was 9.5%, which was significantly higher than that of Combizym® group (1.8%, P<0.05) and combined treatment group (1.8%, P<0.05). There were no serious adverse effects in the three groups.@*Conclusions@#The efficacy of Oryz-Aspergillus enzyme and pancreatin tablets is comparable with that of Mosapride in elderly PDS patients, with fewer adverse effects and low recurrence rate. Combination regimen indicates better efficacy than that of Oryz-Aspergillus enzyme and pancreatin tablets or Mosapride alone.

Effect of needling technique on diabetic gastroparesis and transmembrane protein 16A / 中国针灸

OBJECTIVE@#To observe the therapeutic effect of needling technique (acupuncture for regulating spleen and stomach) on diabetic gastroparesis (DGP), and to explore its possible mechanism.@*METHODS@#A total of 128 patients with DGP were randomized into an observation group (64 cases, 4 cases dropped off) and a control group (64 cases, 4 cases dropped off). On the basis of intervention on controlling blood glucose by western medication, needling technique was adopted at Zhongwan (CV 12), Zusanli (ST 36), Yinlingquan (SP 9), Xuehai (SP 10), Sanyinjiao (SP 6), Diji (SP 8), etc. in the observation group, once a day. Mosapride citrate dispersible tablet 5 mg was given orally 3 times a day in the control group. The treatment was given 6 times a week in the both groups, and totally 4-week treatment was required. Before and after treatment, the DGP symptom score, serum content of transmembrane protein 16A (ANO1) were observed, and the clinical therapeutic effect and the safety were evaluated in the both groups.@*RESULTS@#After treatment, the each subitem score (belching, abdominal distension, inappetence, nausea and vomiting, epigastric pain, abnormal defecation) and the total score of DGP symptom were decreased in both groups (<0.05), the subitem scores of belching, abdominal distension, inappetence, nausea and vomiting and the total score in the observation group were lower than those in the control group (<0.05). After treatment, the serum contents of transmembrane protein 16A were reduced in both groups (<0.05), and that in the observation group was lower than the control group (<0.05). The total effective rate was 86.7% (52/60) in the observation group, which was superior to 70.0% (42/60) in the control group (<0.05). Subcutaneous hematoma occurred in 5 cases in the observation group, which was improved after cold compress without other particular intervention.@*CONCLUSION@#The therapeutic effect of needling technique on improving symptoms in patients with diabetic gastroparesis is superior to mosapride citrate dispersible tablet, its mechanism may be related to alleviating the damage of interstitial cells of Cajal (ICC).

Gastroprokinetic agent, mosapride inhibits 5-HT₃ receptor currents in NCB-20 cells

Mosapride accelerates gastric emptying by acting on 5-hydroxytryptamine type 4 (5-HT₄) receptor and is frequently used in the treatment of gastrointestinal (GI) disorders requiring gastroprokinetic efficacy. We tested the effect of mosapride on 5-hydroxytryptamine type 3 (5-HT₃) receptor currents because the 5-HT₃ receptors are also known to be expressed in the GI system and have an important role in the regulation of GI functions. Using the whole-cell voltage clamp method, we compared the currents of the 5-HT₃ receptors when 5-HT was applied alone or was co-applied with mosapride in cultured NCB-20 cells known to express 5-HT₃ receptors. The 5-HT₃ receptor current amplitudes were inhibited by mosapride in a concentration-dependent manner. Mosapride blocked the peak currents evoked by the application of 5-HT in a competitive manner because the EC₅₀ shifted to the right without changing the maximal effect. The rise slopes of 5-HT₃ receptor currents were decreased by mosapride. Pre-application of mosapride before co-application, augmented the inhibitory effect of mosapride, which suggests a closed channel blocking mechanism. Mosapride also blocked the opened 5-HT₃ receptor because it inhibited the 5-HT₃ receptor current in the middle of the application of 5-HT. It accelerated desensitization of the 5-HT₃ receptor but did not change the recovery process from the receptor desensitization. There were no voltage-, or use-dependency in its blocking effects. These results suggest that mosapride inhibited the 5-HT₃ receptor through a competitive blocking mechanism probably by binding to the receptor in closed state, which could be involved in the pharmacological effects of mosapride to treat GI disorders.

Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Two Cases and Brief Literature Review

It has been reported that there are a range of causative drugs related to symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). The causative drugs reported so far include the following: antibiotics, intravenous immunoglobulin, chemotherapeutic agents, and biologics. In this study, we report two cases of SDRIFE and a review of the previous literature. We believe that our study makes a significant contribution to the literature because it demonstrates that intradermal injection of the Chinese herbal ball, and not its topical application, elicited a reaction that predicted the occurrence of SDRIFE. This finding is important for the diagnosis of SDRIFE in future studies. Our findings also provide evidence for a SDRIFE reaction after exposure to ranitidine and mosapride.

Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial

BACKGROUND/AIMS: To evaluate the efficacy and safety of a controlled release, once-daily formulation of mosapride (UI05MSP015CT) in patients with functional dyspepsia (FD). METHODS: Patients with FD were randomly assigned (1:1) to receive either UI05MSP015CT (15 mg once a day, study group) or mosapride (5 mg three times a day, control group) and corresponding placebo for 4 weeks. The primary endpoint was a change in the gastrointestinal symptom score (GIS) evaluated at enrollment and after 4 weeks. Secondary endpoints were changes in the Nepean Dyspepsia Index-Korean version (NDI-K), rate of satisfactory symptom relief, and rate of adverse events. RESULTS: A total of 138 patients were enrolled (female, 73.9%; mean age, 44.0±15.4 years). After excluding patients who violated the study protocol, 59 and 58 patients from the study and control groups, respectively, were included in the per-protocol analysis. No difference was observed in drug compliance between the control and study groups (97.07%±4.52% vs 96.85%±6.05%, p=0.870). Changes in GIS scores were 9.69±6.44 and 10.01±5.92 in the study and control groups. The mean difference in GIS change between groups was 0.33 (95% confidence interval, 1.75 to 2.41), demonstrating non-inferiority of UI-05MSP015CT (p=0.755). The rate of satisfactory symptom relief was not different between the study and control groups (39.0% vs 56.9%, p=0.053). No differences in change in NDI-K score (14.3 vs 16.9, p=0.263) or rates of adverse events (12.9% vs. 4.4%, p=0.062) were observed between the study and control groups. CONCLUSIONS: Once-daily mosapride is not inferior to conventional mosapride in efficacy and is safe in patients with FD.

Clinical Observation of Prucalopride in the Treatment of Chronic Constipation / 中国药房

OBJECTIVE:To observe therapeutic efficacy and safety of prucalopride in the treatment of chronic constipation (CC). METHODS:Totally of 100 CC patients were selected from anorectal department of our hospital during Jun. 2016-Jan. 2017, and then divided into control group and observation group according to random number table,with 50 cases in each group. Control group was given Mosapride citrate tablets 5 mg +Lactulose oral solution 10 mL orally,3 times a day. Observation group was given Prucalopride succinate tablets 2 mg orally,once a day. Both groups were treated for consecutive 4 weeks. Clinical efficacies of 2 groups were observed,and the levels of serum inflammatory factors(IL-6,TNF-α,IFN-γ)and colonic transit time(total colonic transit time,left colonic transit time,right colonic transit time,rectosigmoid colonic transit time)were observed before and after treatment. The occurrence of defecation disorders and ADR were recorded. RESULTS:None of patient in 2 groups was cured. Total response rate of observation group was 94.00%,which was significantly higher than 78.00% of control group,with statistical significance (P＜0.05). Before treatment,there was no statistical significance in the levels of serum inflammatory factors or colonic transit time (P＞0.05). After treatment,the levels of IL-6 and IFN-γ in control group,the levels of IL-6,TNF-α and IFN-γ in observation group were decreased significantly,and the levels of IL-6,TNF-α and IFN-γ in observation group were significantly lower than those of control group;the colonic transit time in 2 groups was shortened significantly,and observation group was significantly shorter than control group,with statistical significance (P＜0.05). After treatment,the incidence of defecation,incomplete emptying,sense of obstruction and sense of rectal tenesmus in observation group were significantly lower than control group,with statistical significance(P＜0.05). There was no statistical significance in the incidence of sense of rectal tenesmus after treatment or ADR between 2 groups (P＞0.05). CONCLUSIONS:Compared with traditional plan of mosapride combined with lactulose,prucalopride can more effectively reduce the levels of serum inflammatory factors,shorten colonic transit time,reduce the occurrence of defecation disorders as defecation and incomplete emptying,with equivalent safety.

Clinical effect of mosapride combined with rabeprazole in the treatment of elderly patients with reflux esophagitis / 中国基层医药

Objective To explore the clinical effect of mosapride combined with rabeprazole in the treatment of elderly patients with reflux esophagitis .Methods Clinical data of 126 elderly patients with reflux esophagitis were retrospectively studied.64 cases in the study group were treated with mosapride combined with rabeprazole ,62 cases in the control group were treated with mosapride combined with omeprazole .The clinical effects between the two groups were compared.Results Before treatment,there were no statistically significant differences in the scores of pain of patients with heartburn,acid reflux and chest between the two groups (t =0.512,0.181,0.228,all P >0.05). After treatment,the symptom scores of the study group were significantly lower than those of the control group (t =3.689,4.892,5.571,all P <0.01).The clinical symptoms and esophageal mucosal total effective rate in the study group were significantly higher than those in the control group (96.88% vs.87.10%,93.75% vs.80.65%,χ2 =4.121,4.479,all P <0.05).The scores of quality of life scale of the study group were significantly higher than those of the control group in cognitive function ,mental function,physical function and social function (t =4.920,6.853, 4.153,6.163,all P <0.01).Conclusion Mosapride combined with rabeprazole in the treatment of elderly patients with reflux esophagitis can effectively relieve symptoms of heartburn ,acid reflux and chest pain,help patients with mucosa recovery as soon as possible ,improve the quality of life of patients,and it is worthy of clinical application .

Observation of the clinical curative effect of flupentixol/melitracen combined with mosapride citrate in the treatment of functional dyspepsia / 中国基层医药

Objective To investigate the clinical curative effect of flupentixol/melitracen (deanxit) combined with mosapride citrate in the treatment of functional dyspepsia.Methods The clinical data of 240 patients with functional dyspepsia were collected,According to different treatment method,they were divided into two groups,120 patients of the control group were treated with mosapride citrate combined with omeprazole,120 patients of the observation group were treated with deanxit combined with mosapride citrate.One course of treatment was 4 weeks.After one course of treatment,the clinical curative effects and adverse reactions of the two groups were evaluated.Results After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the two groups were significantly lower compared with before treatment,the differences were statistically significant (all P ＜ 0.05).After treatment,the abdominal distension,abdominal pain,early satiety,belching and other symptoms scores of the observation group were significantly lower than those in the control group,the differences were statistically significant(all P ＜ 0.05).The clinical total effective rate of the observation group was 90.8％,which was significantly higher than 67.5 ％ of the control group,the difference was statistically significant (x2 =8.432,P ＜ 0.05).Before and after treatment,the liver and kidney function and blood in the urine routine examination in the two groups had no significant changes.The incidence rate of adverse reactions of the observation group was 11.67％,which of the control group was 15.83 ％,there was no statistically significant difference (x2 =0.911,P ＞ 0.05).Conclusion Deanxit combined with mosapride citrate in the treatment of functional dyspepsia is one of the important method,and its clinical effect is satisfactory,relatively safe,it is worthy of popularization and application.

Mosapride citrate in reflux esophagitis treatment and intervention effect analysis / 中国生化药物杂志

Objective To explore the use of mosapride citrate in treating reflux esophagitis and nursing intervention spitley effect. Methods In 40 cases of reflux esophagitis in patients with routine therapy, and classified as the control group, the other 40 patients in the control group based on the use of mosapride citrate. And classified as the observation group, two groups of patients were in our hospital from June 2015 to January 2017. Results The study in the treatment of the two groups of patients with effective rate of 95.0%, the observation group was significantly higher than the control group 80.0%, between the two groups showed significant differences (P<0.05). The adverse effects of more than two groups found, two groups of patients with adverse reaction incidence was no significant difference, that shows no significant difference. Conclusion Mosapride citrate in reflux esophagitis treatment and intervention effect analysis found that the compared with conventional therapy, can be in At the same time, it can improve the curative effect of the patients, and will not increase the possibility of adverse reactions, so it is worthy of clinical reference.

Comparison of short-term curative effects of prucalopride and mosapride respectively combined with low dose polyethylene glycol in treating elderly refractory functional constipation / 重庆医学

Objective To compare the short-term curative effects of prucalopride and mosapride respectively combined with low dose polyethylene glycol in treating elderly refractory functional constipation.Methods Ninety patients with elderly refractory functional constipation in the outpatient department of our hospital from May 2014 to February 2016 were retrospectively analyzed and divided into two groups randomly,45 cases in each group.the prucalopride group:Prucalopride Succinate Tablets,2mg,4 times daily;the mosapride group:Mosapride Citrate Capsules,5mg,3 times daily.Polyethylene Glycol Electrolytes Powder(PEG) was also used in the two groups,13.125g,twice daily.The course of treatment was 4 weeks.The first defecating time and defecation difficulty relief time,average weekly spontaneous complete bowel movements (SCBM),defecating difficulty,stool character,adverse reactions and change of life quality were observed in the two groups.Results The treatment effective rate of slow transit constipation(STC) and defecatory disorder had the statistical difference between the two groups (P0.05).Compared with the mosapride group,the first defecating time and defecation difficulty relief time in the prucalopride group were shorter with statistical difference (P0.05).The total effective rate had statistical difference between the two groups(P<0.05).The incidence rate of adverse reactions had no statistical difference between the two groups(17.78% vs.15.56%,P<0.05).The total average score of PAC-QOL after treatment in the two groups were both decreased,moreover the decrease in the prucalopride group was more obvious;the difference between the two groups had statistical significance(P<0.05).Conclusion Prucalopride +PEG take effect faster in the treatment of elderly refractory functional constipation and has the advantages in the aspects of overall curative effect and life quality improvement,which is specially suitable for STC and defecatory disorder type.

Value and effect evaluation of Rabeprazole Combined with Mosapride in the Treatment of Reflux Esophagitis / 中国生化药物杂志

Objective To investigate the efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis. Methods A total of 92 patients with reflux esophagitis admitted from April 2016 to April 2017 in our hospital were divided into study group and routine group (n = 46). The routine group was treated with omeprazole and Mosapride,the study group was treated with rabeprazole and mosapride. The clinical efficacy and adverse reactions in the two groups were observed and compared. Results The total effective rate was 91.30％ in the study group and 76.09％ in the conventional group, the difference was statistically significant (P<0.05). The total effective rate of reflux symptoms, esophageal irritation and esophageal irritation was significantly higher in the study group than in the conventional group (P<0.05)The adverse reaction rate was 4.35％ in the study group and 6.52％ in the conventional group, the difference was not statistically significant (P<0.05). Conclusion In the course of clinical treatment of reflux esophagitis, attention should be paid to the two aspects of acid suppression and gastric motility. In the inhibition of acid, the effect of Bella is obviously higher than that of omeprazole. In gastric motility, mosapride in clinical effect is better. Reflux esophagitis by rabeprazole combined with mosapride treatment, clinical efficacy is significant, and adverse reaction rate is low, safe and reliable, worthy of clinical application.

Clinical observation of rabeprazole combined with mosapride in the treatment of reflux esophagitis / 中国生化药物杂志

Objective To explore the clinical efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis.MethodsThe clinical data of 315 patients with reflux esophagitis from December 2015 to December 2016 in our hospital were retrospectively analyzed, were randomly divided into two groups according to the time of admission.The control group (157 cases)was treated with rabeprazole, the observation group (158 cases) given rabeprazole combined with mosapride treatment.The clinical symptom scores before and after treatment, the effective rate of treatment, the quality of life before and one month after treatment and three months after treatment of two groups were compared.ResultsAfter treatment,the symptoms scores of the two groups were significantly lower than those before treatment, but the the scores in the observation group were significantly lower than those in the control group (P<0.05);The total effective rate was 96.2% in the observation group, which was significantly higher than that in the control group (79.0%), the difference between the two groups was statistically significant (P<0.05);The quality of life scores of the two groups were significantly higher than that before treatment, but the scores of one months after treatment and three months after treatment in observation group were significantly higher than those in control group (P<0.05).ConclusionReflux esophagitis with rabeprazole combined with mosapride treatment is significant,can better improve the clinical symptoms of patients, improve the treatment efficiency, and improve the quality of life of patients.

Controlled Clinical Study on Electroacupuncture at the Acupoints on Extremities Predominantly for Functional Dyspepsia / 上海针灸杂志

Objective To observe the therapeutic efficacy of electroacupuncture at the acupoints on extremities or abdominal acupoints and orally taking Mosapride in treating functional dyspepsia (FD) and the different effects on life style, for guiding the points selection in acupuncture-moxibustion treatment for FD.Method Sixty FD patients were randomized into an extremity-electroacupuncture group, an abdomen-electroacupuncture group, and a Western medication group by their visiting sequence, 20 cases in each group. In theextremity-electroacupuncture group, Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6) and Gongsun (SP4) were selected. Bilateral Zusanli and Sanyinjiao were respectively connected to G6805-2 electroacupuncture apparatus, 30 min for each session, once everyother day, 10 sessions in total. In the abdomen-electroacpuncture group, Zhongwan (CV12), Tianshu (ST25), and Qihai (CV6) were selected. Bilateral Tianshu were connected to electroacupuncture apparatus, with same treatment time, frequency and sessions. The Western medication group was intervened by oral administration of Mosapride, 1 tablet each time, 3 times a day, for 20 d in total. The three groups were evaluated by using Nepean Dyspepsia Index (NDI) prior to the treatment, after the treatment and 1 month after the treatment (follow-up study), and the therapeutic efficacies were estimated after the treatment.Result The effective rate of the extremity-electroacupuncture group was higher than that of the abdomen-electroacupuncture group and Western medication group, while there was no significant difference between the abdomen-electroacupuncture group and Western medication group in comparing the effective rate. After the treatment, the improvement of Nepean Dyspepsia Symptom Index (NDSI) in the extremity-electroacupuncture group was more significant than that in the abdomen-electroacupuncture group and Western medication group (P0.05). The 1-month follow-up showed that the improvement of symptoms in the extremity-electroacupuncture group was more significant than that in the abdomen-electroacupuncture group (P0.05). The 1-month follow-up study showed that the quality of life in the extremity-electroacupuncture group was still significantly improved compared to that before the treatment, while the improvement in the Western medication group was insignificant.Conclusion Electroacupuncture at the acupoints on extremities and abdominal acupoints both can more effectively and consistently improve the symptoms and quality of life of FD patients compared to orally taking Mosapride. Compared to electroacupuncture at the abdominal acupoints, electroacupuncture at the extremity points works better in improving the symptoms of FD butdoesn't show advantage in improving the quality of life.

Analysis of curative effect of compound azinomide and mosapride in the treatment of senile gastrointestinal diseases associated with indigestion / 中国生化药物杂志

Objective To explore the compound azintamide + mosapride application regimen in elderly patients with gastrointestinal diseases and associated dyspepsia in the treatment. Methods 116 cases of elderly patients with gastrointestinal disease associated dyspepsia patients treated in our hospital from April 2016 to April 2017 were randomly divided into observation group and control group, with 58 cases in each group. The observation group was treated with azintamide + mosapride,the control group was treated with mosapride,the two groups were treated for 28 d .The total score of dyspeptic symptoms before and after treatment in two groups was recorded, and the clinical symptoms were evaluated according to the remission rate of symptom scores. The incidence of adverse reactions in the two groups was calculated and compared between the two groups. Results There was no significant difference in total scores of dyspepsia symptoms between two groups before treatment. The total score of the two groups of dyspepsia symptoms decreased in different degrees after the end of the effective course,the observation group was significantly better than the control group (P<0.05). The effective rate of the observation group was 87.9%, which was significantly higher than that of the control group (60.3%) (P<0.05). Conclusion Compound azintamide combined with Mosapride is effective in the treatment of gastrointestinal diseases associated dyspepsia in elderly patients, combination therapy significantly improved in patients with dyspeptic symptoms, improve the quality of life of patients, clinical application of feedback is good, safe and reliable.

Curative effect of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia and Influence on brain-gut peptide / 中国综合临床

Objective To investigate the curative effect and mechanism of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia(FD).Methods One hundred and ten cases patients with FD were divided into two groups according to the digital random table method,with 55 cases in each group.The control group took mosapride tablets orally(5 mg/times,3 times/d,30 min before meals),the treatment group took with Shugan Jieyu capsule orally(2 pellets/times,2 times/d,orally with warm water on morning and evening)on the basis of treatment of the control group.Two groups were treated continuously for 4 weeks.The symptoms score and total effective before and after treatment were compared,and plasma Leptin(Leptin),Ghrelin and gastric dynamic element(MTL)levels of the two groups before and after treatment were compared.The two groups were followed up for 6 months after treatment,the recurrence rate of the two groups was compared.Results The symptoms integral of the treatment group after treatment was lower than that of the control group((4.97±1.85)points vs.(7.35±2.28)points,t=6.011,P＜0.01),the total effective rate was higher than that of the control group(94.5％(52/55)vs.81.8％(45/55),x2=4.274,P=0.039),the improvement of plasma Leptin((13.10±2.07)μg/L vs.(14.66±2.11)μg/L,t=3.914,P=0.001),Ghrelin((3.52±0.70)ng/L vs.(2.95±0.67)ng/L,t=4.363,P＜0.01),MTL((281.47±61.09)ng/L vs.(242.31±65.28)ng/L,t=3.248,P=0.002)levels were better than those of the control group,the recurrence rate of 6 months was lower than that of the control group(7.5％(5/53)vs.24.4％(11/45),x2=4.124,P=0.041),the difference was statistically significant.Conclusion Mosapride tablets combined with Shugan Jieyu capsule can benefit the liver symptom,and also can reduce the recurrence rate,it has curative effect on FD,its mechanism may be related to the improvement of BGP levels disorder in patients with FD.

Effect of mosxapride citrate on gastrin in patients with gastroesophageal reflux / 中国生化药物杂志

Objective To study the effect of mosapride citrate in the treatment of gastroesophageal reflux disease and its effect on gastrin .Methods 86 patients with gastroesophageal reflux disease admitted in our hospital from August 2013 to August 2016, those patients were divided into observation group and control group according to the order of admission,43 cases in each group.The control group was treated with esomeprazole on the basis of basal therapy, and the observation group was treated with mosapride citrate on the basis of control group.The clinical curative effect and adverse reaction were analyzed,visual analogue scale(VAS), gastrin and motilin were compared before and after treatment between the two groups.Results After treatment, the total effective rate in the observation group was significantly higher than the control group [90.70% (39/43) vs.65.12% (28/43)](P<0.05). The VAS score in the observation group was significantly lower than the control group [(2.43 ±0.25) vs.(4.02 ±0.41)](P<0.05).The levels of gastrin and motilin in the observation group were significantly higher than the control group[ (55.87 ±4.82) pg/mL, (308.43 ±19.31) pg/mL vs. (44.12 ±3.86) pg/mL,(243.12 ±15.76) pg/mL](P<0.05).There was no significant difference in adverse reaction rate between two groups. Conclusion Mosapride citrate tablets can be used in gastroesophageal reflux disease , can effectively improve the patient's gastrin levels and clinical symptoms, clinical efficacy is good, and with low rate of adverse reactions.

Clinical efficacy of esomeprazole, mosapride, magnesium plus aluminum in reflux esophagitis / 中国生化药物杂志

Objective To investigate clinical effect of esomeprazole, mosapride, magnesium plus aluminum in patients with reflux esophagitis. Methods 98 patients with reflux esophagitis who were treated in our hospital from October 2014 to October 2016 were selected and randomly divided into control group and observation group, with 49 cases in each group.In the control group, patients were treated with esomeprazole and mosapride.In the observation group, patients were given esomeprazole, mosapride and magnesium plus aluminum.The levels of serum gastrin, serum motilin and 24-hour pH in the esophagus were compared before and after treatment .Results After treatment,The levels of serum gastrin and serum motilin in the observation group were significantly higher than those in the control group, the difference was statistically significant (P<0.05), while the total time percentage of pH<4 at standing position, total time percentage of pH <4 at supine position, total reflux time percentage of pH <4, and the duration of continuous reflux≥five mins in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05). Conclusion Esomeprazole, mosapride and magnesium plus aluminum have significant clinical effect in patients with reflux esophagitis, and can effectively reduce 24-hour pH in the esophagus, decrease the number of reflux, increase serum gastrin and serum motilin levels.

Intestinal Absorption Characters of Mosapride Citrate Using Caco-2 Cells and Single-Pass Intestinal Perfusion Methods / 中国药学杂志

OBJECTIVE: To investigate the intestinal absorption characters of mosapride citrate(MC) and its tablets. METHODS: The Caco-2 cell monolayer was cultured and the in situ single-pass intestinal perfusion(SPIP) in rat model was created for studying the drug absorption properties, using phenol red method to revise the perfusate volume, a HPLC method was developed to simultaneously detect the phenol red and MC, the absorptive coefficient of Papp and Peff was calculated. RESULTS: MC was absorbed by the whole intestine segments in rats, mainly at upper small intestine. The tablets showed high permeability and good intestinal absorption in Caco-2 cells and SPIP in rats. CONCLUSION: In the Caco-2 cells and rats SPIP models, the tablets are prepared showed good consistency with the branded drug.